« Return to News | Clinical Intelligence

Insero Health completes phase I trial in drug resistant epilepsy

Thursday, December 13, 2012 08:00 AM

Insero Health, a clinical-stage company that develops small molecule therapies derived from natural products to treat neurological diseases, has completed a phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. 

INS001, also known as huperzine A, is a naturally-occurring compound that has shown promising activity in preclinical epilepsy models.  It has previously demonstrated good safety and signs of therapeutic activity in a phase II trial in Alzheimer's disease and in preclinical models of multiple sclerosis and neuropathic pain.

The phase Ib epilepsy trial included dose ranging assessments, as well as biomarkers chosen to provide information on the potential therapeutic activity and cardioprotective properties of INS001. Insero expects to report the results of the phase Ib trial in the next few months and to initiate phase II proof-of-principle trials by early 2014.

Insero also reported that two key U.S. patents licensed from Harvard University have issued. The two patents were exclusively licensed to Insero by Harvard University and cover the use of INS001 as a treatment for epilepsy and other indications. The company also has licensed technology patents from Yale University and the University of South Florida. In addition, Insero is continuing its research programs related to its library of over 5,000 proprietary compounds, including screening for potential utility in epilepsy and other related neurological disorders.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.